{"denoms":[{"counts":[{"groupId":"BG000","value":"152"}],"units":"Participants"}],"groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"BG000","title":"Relacorilant (OL Phase)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.23","value":"50.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"123"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"121"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"24.660","value":"93.77"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"32.675","value":"34.738"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Mass Index (BMI)","unitOfMeasure":"kg/m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"18.0355","value":"114.85"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Waist circumference","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}]}],"description":"HTN is defined as mean systolic blood pressure (SBP) ≥135 or ≤170 mm Hg and/or mean diastolic blood pressure (DBP) ≥85 to ≤110 mm Hg.","paramType":"COUNT_OF_PARTICIPANTS","title":"Hypertension (HTN) only","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}]}],"description":"DM is defined as fasting plasma glucose ≥126 mg/dL and/or oral glucose tolerance test plasma glucose ≥200 mg/dL or hemoglobin A1c (HbA1c) ≥6.5%. IGT is defined as plasma glucose ≥140 mg/dL and \\<200 mg/dL on a 2-hour oral glucose tolerance test.","paramType":"COUNT_OF_PARTICIPANTS","title":"Diabetes mellitus (DM) or impaired glucose tolerance (IGT) only","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71"}]}]}],"description":"HTN and DM/IGT as previously defined.","paramType":"COUNT_OF_PARTICIPANTS","title":"HTN and DM/IGT","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population was patients in the Intent-to-Treat (ITT) Population which included all enrolled patients who received at least 1 dose of study drug."}